Cargando cotizaciones...
Previsión
| Comprar |
2 |
| Mantener |
1 |
| Vender |
0 |
Noticias Ir al feed de noticias
SINTX reports strong revenue growth in Q2 2026, stock falls after hours
SINTX recorded a 199% revenue increase in the second quarter of 2026 to $452,000 and improved its gross margin to 61.5%, while net loss widened to $2.7 million. The company reported initial commercial revenues for the SINAPTIC-Wedge system and orders from contract manufacturing customers of about $3.2 million. The stock finished the regular session slightly higher but declined after hours as investors weighed continued losses, high cash burn (cash $3.6 million) and doubts about the company’s ability to continue as a going concern. Management guidance sees revenue of $0.9–1.1 million for Q3 2026 and $1.0–1.3 million for Q4, and the company emphasized additional financing needs and ongoing execution risks. » Más en de.investing.com
SINTX signs supply agreement with EVONIK for SiN/PEEK composite for AI-assisted 3D printing manufacturing
SINTX Technologies has signed a supply agreement with Evonik for the industrial production of its patented silicon nitride‑PEEK (SiN/PEEK) composite for AI‑assisted additive manufacturing of patient‑specific implants. Evonik will produce the scalable composite filament to SINTX specifications, enabling SINTX to begin immediate manufacture of 3D‑printed vertebral body replacement implants and other indications. SINTX highlights the material’s antipathogenic surface properties, osteogenic potential and improved imaging, and intends to use it to support regulatory approvals and humanitarian applications. » Más en finanzen.net
SINTX Technologies closes private-label deal for OsseoSculpt and plans market launch
SINTX Technologies has signed a private-label agreement to supply the biologic OsseoSculpt, intended to complement the FDA‑cleared SINAPTIC Foot & Ankle Osteotomy Wedge System. The company reports initial commercial revenue from OsseoSculpt in Q3 2025 and plans a limited rollout at early‑adopter sites with a broader US launch in Q1 2026. In parallel, SINTX received 510(k) clearance for the SINAPTIC wedge system, a Notice of Allowance for an anti‑pathogenic silicon nitride technology, and raised about $3.8 million through option exercises, but remains under profitability pressure with negative EBITDA and sharply declining revenues. » Más en de.investing.com
Dividendos históricos Dividendos
Todas las métricas de dividendos Todas las métricasDatos financieros de la empresa
| (EUR) | jun 2026 | |
|---|---|---|
| Ingresos | 396,05k | 366,81% |
| Beneficio bruto | 243,59k | 4.685,10% |
| Beneficio neto | −2,37M | 20,56% |
| EBITDA | −2,31M | 26,32% |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 8,35M€ |
Número de acciones | 6,36M |
Máximo/mínimo de 52 semanas | 5,82€ - 1,20€ |
| Dividendos | No |
Beta | 0,64 |
Ratio P/E | −0,28 |
Ratio PEG | 0,00 |
Ratio P/B | 1,54 |
Ratio P/S | 7,04 |
Perfil de la empresa
Sintx Technologies, Inc. ist ein Unternehmen für hochentwickelte Materialien, das sich mit der Erforschung, Entwicklung und Vermarktung von medizinischen Geräten beschäftigt, die mit Siliziumnitrid für biomedizinische, industrielle und antipathogene Anwendungen hauptsächlich in den Vereinigten Staaten hergestellt werden. Das Unternehmen bietet festes und poröses Siliziumnitrid, Siliziumnitrit-Pulver und Siliziumnitrid-Beschichtungsprodukte sowie Siliziumnitrid-Verbundwerkstoffe und Polyetherketonketon an. Das Unternehmen war früher unter dem Namen Amedica Corporation bekannt. Sintx Technologies, Inc. wurde 1996 gegründet und hat seinen Hauptsitz in Salt Lake City, Utah.
| Nombre | SINTX Technologies Inc |
| CEO | Eric K. Olson |
| Sede | Salt Lake City,
ut Estados Unidos |
| Sitio web | |
| Sector | Materiales |
| Industria | Productos químicos |
| Salida a bolsa | 13/02/2014 |
| Empleados | 32 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NASDAQ | SINT |
Frankfurt | 111A.F |
London | 0A8S.L |
München | 111A.MU |
Descubrir activos
Los accionistas de SINTX Technologies Inc también invierten en los siguientes activos




